These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49 related articles for article (PubMed ID: 121616)
1. [Pseudomonas aeruginosa sepsis caused by an intravenous catheter and successfully treated with amikacin]. Sellen Crombet J; Aguirregabiria Ruíz L; Sánchez Casas A Rev Cubana Med Trop; 1979; 31(3):245-50. PubMed ID: 121616 [TBL] [Abstract][Full Text] [Related]
2. [The use of amikacin in the treatment of endometritis caused by Pseudomonas aeruginosa in mares]. van Dyk E; Immelman A; van Heerden JS J S Afr Vet Assoc; 1982 Jun; 53(2):124-6. PubMed ID: 6811742 [TBL] [Abstract][Full Text] [Related]
3. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy. Leonard JM; McGee ZA; Alford RH Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674 [TBL] [Abstract][Full Text] [Related]
4. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Lau WK; Young LS; Osher AB; Dooley RR Pediatrics; 1977 Sep; 60(3):372-7. PubMed ID: 408787 [TBL] [Abstract][Full Text] [Related]
5. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey. Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175 [TBL] [Abstract][Full Text] [Related]
6. Analysis of amikacin-resistant Pseudomonas aeruginosa developing in patients receiving amikacin. Maloney J; Rimland D; Stephens DS; Terry P; Whitney AM Arch Intern Med; 1989 Mar; 149(3):630-4. PubMed ID: 2493230 [TBL] [Abstract][Full Text] [Related]
7. Amikacin therapy for Pseudomonas cellulitis in an Amazon parrot. Junge RE; MacCoy DM J Am Vet Med Assoc; 1985 Aug; 187(4):417-8. PubMed ID: 4030478 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats. Johnson DE; Thompson B Am J Med; 1986 May; 80(5C):53-8. PubMed ID: 3636060 [TBL] [Abstract][Full Text] [Related]
9. Transduction of amikacin, gentamicin and tobramycin resistance in Pseudomonas aeruginosa with phage F 116 and AP 19, a new wildtype phage. Knothe H; Lebek G; Krcméry V; Seginková Z; Cervenka J; Antal M; Mitsuhashi S Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981 Nov; 250(4):506-10. PubMed ID: 6800151 [TBL] [Abstract][Full Text] [Related]
10. Experimental infection in rabbits evoked by Pseudomonas aeruginosa, Proteus mirabilis, Escherichia coli and Klebsiella pneumoniae treated with gentamicin, amikacin and sisomicin. Jeljaszewicz J; Włodarczak K; Bis W; Kazanowski A; Kuzniewski P; Molska J Zentralbl Bakteriol A; 1980 Aug; 247(3):347-52. PubMed ID: 6999802 [TBL] [Abstract][Full Text] [Related]
11. Transferable amikacin and cefamandole resistance: Pseudomonas maltophilia and Acinetobacter strains as possible reservoirs of R plasmids. Krcméry V; Langsádl L; Antal M; Seckárová A J Hyg Epidemiol Microbiol Immunol; 1985; 29(2):141-6. PubMed ID: 3926873 [TBL] [Abstract][Full Text] [Related]
13. Antibiotic use in neonatal sepsis. Yurdakök M Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468 [TBL] [Abstract][Full Text] [Related]
14. Clinical and microbiologic consequences of amikacin use during a 42-month period. Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526 [TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E; Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983 [TBL] [Abstract][Full Text] [Related]
17. Transduction of amikacin, gentamicin and tobramycin resistance in Pseudomonas aeruginosa. Knothe H; Krcméry V; Mitsuhashi S Zentralbl Bakteriol A; 1980 Mar; 246(3):373-8. PubMed ID: 6775445 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics. Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591 [TBL] [Abstract][Full Text] [Related]
19. Amikacin resistance developing in patients with Pseudomonas aeruginosa bronchopneumonia. Amirak ID; Williams RJ; Noone P; Wills MR Lancet; 1977 Mar; 1(8010):537-8. PubMed ID: 65626 [No Abstract] [Full Text] [Related]
20. [Bacteriological monitoring of the treatment of Pseudomonas aeruginosa infections with amikacin administrated at once-daily dosis in patients with cystic fibrosis]. Canis F; Husson MO; Vic P; Ategbo S; Turck D; Courcol R; Leclerc H Pathol Biol (Paris); 1995 Apr; 43(4):343-51. PubMed ID: 7567127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]